Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.

摘要: Abstract Purpose This study evaluated changes in weight, glucose and lipid metabolism patients with schizophrenia antipsychotic-related metabolic disturbances who were switched to ziprasidone. Methods Eighty-four outpatients or schizoaffective disorder also having intolerance, diabetes, dyslipidemia weight gain related their antipsychotic treatment Clinical status was assessed using the Global Impression of Severity (CGI-S) Improvement (CGI-I) scales Positive Negative Syndrome Scale (PANSS). Assessment scales, lipids measured at baseline three six months ziprasidone treatment. Results Significant endpoint reductions seen mean (− 5.1 kg), Body Mass Index (BMI; − 1.6 kg/m 2 ), serum (− 14.0 mg/dL), total cholesterol (− 24.1 mg/dL), triglyceride leves (− 46.2 mg/dL). Mean PANSS score improved 13.9% after 6 months A proportion (34.3%) classified as much CGI-I. Conclusions Switching when are detected may improve these side effects result an overall outcome.